Cytosolic Catechols Inhibit α-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aberrant aggregation of α-synuclein (α-syn) to form fibrils and insoluble aggregates has been implicated in the pathogenic processes of many neurodegenerative diseases. Despite the dramatic effects of dopamine in inhibiting the formation of α-syn fibrils by stabilization of oligomeric intermediates in cell-free systems, no studies have examined the effects of intracellular dopamine on α-syn aggregation. To study this process and its association with neurodegeneration, intracellular catechol levels were increased to various levels by expressing different forms of tyrosine hydroxylase, in cells induced to form α-syn aggregates. The increase in the steady-state dopamine levels inhibited the formation of α-syn aggregates and induced the formation of innocuous oligomeric intermediates. Analysis of transgenic mice expressing the disease-associated A53T mutant α-syn revealed the presence of oligomeric α-syn in nondegenerating dopaminergic neurons that do contain insoluble α-syn. These data indicate that intraneuronal dopamine levels can be a major modulator of α-syn aggregation and inclusion formation, with important implications on the selective degeneration of these neurons in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“Previous reports have indicated that expression of -syn induces cellular degeneration that can be attributed to a multitude of events, such as lysosomal and proteosomal dysfunction (Stefanis et al., 2001; Cuervo et al., 2005), sequestration of anti-apoptotic proteins during conditions of oxidative stress (Xu et al.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Self-citationKinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · cited 2×
“…ring can inhibit -syn in vitro (Conway et al., 2001), we speculate that intracellular DA has the greatest effect in vivo because of its ability to auto-oxidize more rapidly than other catechols at physiological pH to generate reactive electrophiles and reactive oxygen species (Graham, 1978).”
BackgroundInitiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · cited 2×
“…interaction with other proteins, such as tau, that leads to an ordered coassembly of the two proteins primarily to homopolymeric fibrils (Giasson et al., 2003); post-translational modifications such as phosphorylation at Ser 129 (Fujiwara et al., 2002; Chen and Feany, 2005; Smith et…”
BackgroundSelf-citationCabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684 · cited 1×
“Several tg mouse lines expressing A53T -syn have been generated and characterized, and the lack of pathology in the SN appears to be a consistent feature (Matsuoka et al., 2001; Giasson et al., 2002; Martin et al., 2006) despite pathology in many other brain regions.”
Background
Cited by
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
“…of protofibrils to mature fibrils in vitro and in vivo, presumably through the formation of dopamine/ a-synuclein adducts (Conway et al. 2001; Mazzulli et al. 2006; Tsika et al. 2010), suggesting that the preferential vulnerability of dopaminergic neurons to the pathogenic process of PD may…”
BackgroundMazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citationα-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Complexity of dopamine metabolism
Meiser, J., Weindl, D., & Hiller, K. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-34 · Cited by 663
Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation
Jeong, H., Then, F., Melia, T. J., Mazzulli, J. R., Cui, L., Savas, J. N., Voisine, C., Paganetti, P., Tanese, N., Hart, A. C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.018 · Cited by 419
Self-citationThe two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases
Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007) · IUBMB Life · doi:10.1080/15216540701283882 · Cited by 335
Oxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N. J., Jeon, S., Burbulla, L. F., Patnaik, S., Sidransky, E., Marugan, J. J., Sue, C. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0628-16.2016 · Cited by 273
Self-citationSpecificity and Regulation of Casein Kinase-Mediated Phosphorylation of α-Synuclein
Waxman, E. A., & Giasson, B. I. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3186fc995 · Cited by 209
Self-citationMitochondrial translocation of α-synuclein is promoted by intracellular acidification
Cole, N. B., DiEuliis, D., Leo, P., Mitchell, D. C., & Nussbaum, R. L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.012 · Cited by 185
“α-Synuclein is a presynaptic neuronal protein that, when expressed in most non-neuronal cells, is diffusely distributed throughout the cytosol with little accumulation at specific intracellular sites [24,34,35].”
BackgroundProtein Oxidation in Aging: Does It Play a Role in Aging Progression?
Reeg, S., & Grune, T. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.6062 · Cited by 181
“These dopamine adducts on a-synuclein are able to stabilize the toxic a-synuclein protofibrils and inhibit the further aggregation into less toxic mature fibrils (112, 123).”
BackgroundPost-translational modification of α-synuclein in Parkinson׳s disease
Barrett, P. J., & Timothy Greenamyre, J. (2015) · Brain Research · doi:10.1016/j.brainres.2015.06.002 · Cited by 174
Grammatopoulos, T. N., Jones, S. M., Ahmadi, F. A., Hoover, B. R., Snell, L. D., Skoch, J., Jhaveri, V. V., Poczobutt, A. M., Weyhenmeyer, J. A., & Zawada, W. M. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-1 · Cited by 165
“Others however argue that elevated DA actually inhibits formation of α-synuclein aggregates [54] and that depletion of DA in vivo does not protect from acute toxicity of MPTP [55].”
BackgroundPerfeito, R., Cunha-Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 164
“[123] Mazzulli J.”
BackgroundNovel therapeutic approaches in multiple system atrophy
Palma, J.-A., & Kaufmann, H. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0249-7 · Cited by 24
“Other molecules that have shown some promising results in inhibiting a-syn aggregation include dopamine [63], mannitol [64], catechol-o-methyltransferase inhibitors [65], cinnamon extract [66], and ring-fused pyridones (small organic molecules with antibacterial activity) [67].”
Background
Metadata
- Authors
- Mazzulli, J. R., Mishizen, A. J., Giasson, B. I., Lynch, D. R., Thomas, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-09-27
- Volume
- 26
- Issue
- 39
- Pages
- 10068-10078
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2007852298
- Cited by
- 152
- References
- 12
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.